Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1234

1.

Lymphoproliferative disorder in a lung transplant recipient.

Haji HA, Corwin DS, So JY, Reed RM.

BMJ Case Rep. 2020 Mar 31;13(3). pii: e234532. doi: 10.1136/bcr-2020-234532.

PMID:
32234858
2.

Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder.

Maloney EM, Busque VA, Hui ST, Toh J, Fernandez-Vina M, Krams SM, Esquivel CO, Martinez OM.

JCI Insight. 2020 Mar 26;5(6). pii: 131644. doi: 10.1172/jci.insight.131644.

3.

Atypical malignancies after intestinal transplantation in children: A European single-centre experience.

Gerlach UA, Morland B, Hobin D, Nagy A, Sharif K, Mirza DF, Gupte GL.

Pediatr Transplant. 2020 Mar 25:e13697. doi: 10.1111/petr.13697. [Epub ahead of print]

PMID:
32212293
4.

A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.

Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.

Ann Hematol. 2020 Mar 24. doi: 10.1007/s00277-020-04003-8. [Epub ahead of print]

PMID:
32206854
5.

Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.

Tillman H, Vogel P, Rogers T, Akers W, Rehg JE.

Vet Pathol. 2020 Mar 23:300985820913265. doi: 10.1177/0300985820913265. [Epub ahead of print]

PMID:
32202225
6.

Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder.

Bishnoi R, Minish J, Franke AJ, Skelton WP 4th, Shah CP, Wang Y, Dang NH.

Cureus. 2020 Feb 7;12(2):e6912. doi: 10.7759/cureus.6912.

7.

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.

Hong J, Ni J, Ruan M, Yang M, Dong Q, Li Q.

Int J Hematol. 2020 Mar 11. doi: 10.1007/s12185-020-02844-7. [Epub ahead of print]

PMID:
32162095
8.

Posttransplantation Lymphoproliferative Disease Treated by Retransplantation.

Weum Abrahamsen I, Grønvold BC, Inderberg EM, Mensali N, Mattsson J, Gedde-Dahl T.

Case Reports Immunol. 2020 Feb 25;2020:9403123. doi: 10.1155/2020/9403123. eCollection 2020.

9.

Non-Hodgkin lymphoma after liver and kidney transplantation in children. Experience from one center.

Dembowska-Bagińska B, Wakulińska A, Daniluk I, Teisseyre J, Jankowska I, Czubkowski P, Grenda R, Jarmużek W, Grajkowska W, Małdyk J, Kaliciński P.

Adv Clin Exp Med. 2020 Feb;29(2):197-202. doi: 10.17219/acem/112605.

10.

CD30 expression and survival in posttransplant lymphoproliferative disorders.

Kinch A, Amini RM, Hollander P, Molin D, Sundström C, Enblad G.

Acta Oncol. 2020 Feb 27:1-8. doi: 10.1080/0284186X.2020.1731924. [Epub ahead of print]

PMID:
32102582
11.

Post-transplant Lymphoproliferative Disorder of Naso-orbital Region in Adult Renal Transplant Recipients: A Case Report and Literature Review.

Nimitpanya P, Limpanavongsaen P, Udomkarnjananun S, Jutivorakool K, Vanichanan J.

Transplant Proc. 2020 Feb 20. pii: S0041-1345(19)31601-X. doi: 10.1016/j.transproceed.2020.01.047. [Epub ahead of print]

PMID:
32089317
12.
13.

Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients.

Seo E, Kim J, Oh SH, Kim KM, Kim DY, Lee J.

Pediatr Transplant. 2020 Feb 17:e13666. doi: 10.1111/petr.13666. [Epub ahead of print]

PMID:
32067332
14.

Epstein-Barr Virus Latent Membrane Protein 1 Regulates Host B Cell MicroRNA-155 and Its Target FOXO3a via PI3K p110α Activation.

Hatton O, Smith MM, Alexander M, Mandell M, Sherman C, Stesney MW, Hui ST, Dohrn G, Medrano J, Ringwalt K, Harris-Arnold A, Maloney EM, Krams SM, Martinez OM.

Front Microbiol. 2019 Nov 26;10:2692. doi: 10.3389/fmicb.2019.02692. eCollection 2019.

15.
16.

Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!

Prasad P, Khullar D, Gupta N, Grover R, Chhabra G, Gandhi KR, Gupta S, Bagai S.

CEN Case Rep. 2020 Feb 3. doi: 10.1007/s13730-020-00455-z. [Epub ahead of print]

17.

Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience.

Qin T, Gu XQ, Jeong SS, Song YY, Liu JC, Zheng JX, Xue F, Xia Q.

Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):3-11. doi: 10.1016/j.hbpd.2019.12.005. Epub 2019 Dec 27.

PMID:
31932195
18.

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.

Mika T, Strate K, Ladigan S, Aigner C, Schlegel U, Tischoff I, Tischer-Zimmermann S, Eiz-Vesper B, Maecker-Kolhoff B, Schroers R.

Front Med (Lausanne). 2019 Dec 18;6:295. doi: 10.3389/fmed.2019.00295. eCollection 2019.

19.
20.

Isolated peritoneal lymphomatosis defined as post-transplant lymphoproliferative disorder after a liver transplant: A case report.

Kim HB, Hong R, Na YS, Choi WY, Park SG, Lee HJ.

World J Clin Cases. 2019 Dec 26;7(24):4299-4306. doi: 10.12998/wjcc.v7.i24.4299.

Supplemental Content

Loading ...
Support Center